sharetrader
Page 1132 of 1156 FirstFirst ... 1326321032108211221128112911301131113211331134113511361142 ... LastLast
Results 16,966 to 16,980 of 17333
  1. #16966
    Senior Member
    Join Date
    Jul 2015
    Location
    Napier
    Posts
    942

    Default

    Quote Originally Posted by Hectorplains View Post
    How about FIVE times that: https://www.asx.com.au/asxpdf/201903...9rpz0q0qzh.pdf

    I am not yet convinced about MHI. I am convinced PEB is a poor 'investment.'
    Sorry I meant PEB shares only not the whole market in general. Thanks for the response anyway.

  2. #16967
    Reincarnated Panthera Snow Leopard's Avatar
    Join Date
    Jul 2004
    Location
    Kuching
    Posts
    399

    Default

    Quote Originally Posted by Minerbarejet View Post
    Has anyone else taken the time to dissect the figures contained in the presentation?

    I'm getting an indication that there is a pipeline of cash about to start flowing.

    I'm also getting an indication that there wont be a lot of patients required for a break even situation.
    I found the presentation rather vague where it matters but I have not read much about PEB for a while.

    With expenses at $23M you need the cash from 20,000 US sold tests at US$760 each, or 50,000 (or 60,000?, or more?) NZ sold tests to break even [Does anyone know what a NZ test sells for?].

    But if you reach those figures your expenses will be higher so add more for luck.

    So then you have a breakeven company and it needs to do even more to justify the $100M market cap.

    So while optimism is a wonderful thing and we will all be pleased if PEB stops bleeding cash it is well within the bounds of possibility that this still has a long road ahead to commercial viability let alone being value for money.

    So I will continue to invest my money on travelling down the Adriatic coast of Italy instead.
    om mani peme hum

  3. #16968
    Member
    Join Date
    Aug 2017
    Posts
    55

    Default

    Quote Originally Posted by Minerbarejet View Post
    1: Revenue excludes tests sold in the US for which cash payment has yet to be received, as well as tests completed for patients covered by the CMS. CMS tests account forapproximately 47% of annual US laboratory throughput and Pacific Edge will seek reimbursement for these when it is included in the CMS’s Local Coverage Determination (LCD). Asat 31 March 2019, Pacific Edge has completed and invoiced a total of 17,015 tests for CMS patients in the USA, for which we are yet to be reimbursed.

    I make that nearly 20 million NZD.
    "US customers – patients covered by CMSThe Group has judged it is not probable that any consideration will be received from CMS as inclusion in the LocalCoverage Determination (LCD) with the CMS has not yet been obtained. Therefore, no revenue is recognised forany patients covered by CMS" source - Consolidated Financial Statements

  4. #16969
    Member
    Join Date
    Sep 2002
    Posts
    410

    Default

    Quote Originally Posted by Nigelk View Post
    "US customers – patients covered by CMSThe Group has judged it is not probable that any consideration will be received from CMS as inclusion in the LocalCoverage Determination (LCD) with the CMS has not yet been obtained. Therefore, no revenue is recognised forany patients covered by CMS" source - Consolidated Financial Statements
    Doesn't that just mean that consideration is not probable in the current reporting period and therefore revenue is not included in that period...? That's certainly what this implies...:

    "Importantly, in October, the company received notification of the Cxbladder test national reimbursement rate (US$760) from CMS. Once the company receives Local Coverage Determination (LCD), Pacific Edge will be able to get reimbursement for Medicare claims and will enable reimbursement and negotiation for payment on 14,000 tests previously performed on CMS patients. The LCD process is ongoing and once completed will be a major driver of future growth."

    https://www.edisongroup.com/company/pacific-edge/1973/

    And, yes, I know it's Edison, and that a grain of salt is required....

  5. #16970
    Senior Member
    Join Date
    May 2012
    Posts
    916

    Default

    Quote Originally Posted by BigBob View Post
    Doesn't that just mean that consideration is not probable in the current reporting period and therefore revenue is not included in that period...? That's certainly what this implies...:

    "Importantly, in October, the company received notification of the Cxbladder test national reimbursement rate (US$760) from CMS. Once the company receives Local Coverage Determination (LCD), Pacific Edge will be able to get reimbursement for Medicare claims and will enable reimbursement and negotiation for payment on 14,000 tests previously performed on CMS patients. The LCD process is ongoing and once completed will be a major driver of future growth."

    https://www.edisongroup.com/company/pacific-edge/1973/

    And, yes, I know it's Edison, and that a grain of salt is required....
    Edison don't seem to be known for accuracy....Chairman = Christopher Swann. Wrong Christopher!!

  6. #16971
    Member
    Join Date
    Sep 2002
    Posts
    410

    Default

    Quote Originally Posted by Dentie View Post
    Edison don't seem to be known for accuracy....Chairman = Christopher Swann. Wrong Christopher!!
    LOL... Please see my disclaimer in previous post... :-)

  7. #16972
    Guru
    Join Date
    Apr 2003
    Location
    Wellington, New Zealand
    Posts
    3,241

    Default

    Quote Originally Posted by BigBob View Post
    LOL... Please see my disclaimer in previous post... :-)
    But But....

    An introduction to Edison Group
    The cornerstones of our research brand at Edison Group are integrity, credibility and trust.

    The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

    https://www.edisongroup.com/about-us/

  8. #16973
    Senior Member
    Join Date
    Jul 2015
    Location
    Napier
    Posts
    942

    Default

    back down to 18 cents must be a buy now????? Oh wait DYOR

  9. #16974
    Guru
    Join Date
    Jul 2002
    Location
    New Zealand.
    Posts
    2,794

    Default

    Interesting activity today, WHATSUP ?

  10. #16975
    Guru
    Join Date
    Apr 2003
    Location
    Wellington, New Zealand
    Posts
    3,241

    Default

    Quote Originally Posted by whatsup View Post
    Interesting activity today, WHATSUP ?
    Well Chris Gallagher purchased 200k shares and Sarah Park bought about 23k.

    Normally insiders buying is seen as a bullish signal.

    https://www.nzx.com/announcements/335768

  11. #16976
    Member Timesurfer's Avatar
    Join Date
    May 2018
    Location
    Top of the South
    Posts
    309

    Default

    Quote Originally Posted by Ggcc View Post
    back down to 18 cents must be a buy now????? Oh wait DYOR
    Another great deal for traders.
    One day it might not bounce back and that will burn a few I am guessing.
    “Better three hours too soon than a minute too late.”
    ― William Shakespeare

  12. #16977
    Senior Member
    Join Date
    Jul 2015
    Location
    Napier
    Posts
    942

    Default

    Quote Originally Posted by Timesurfer View Post
    Another great deal for traders.
    One day it might not bounce back and that will burn a few I am guessing.
    It has been amazing for traders. Well done to those who did well I won’t be getting involved in this share again, unless sales increase in the ooo’s percentage in one year

  13. #16978
    Member
    Join Date
    Aug 2017
    Posts
    55

    Default

    I wrote to Pacific Edge seeking clarification on the revenue from CMS tests undertaken. My email is first, then their reply below, then some comments from me.


    I'm a shareholder seeking clarification on some statements made by Pacific Edge about revenue recognition for tests on CMS patients.


    One statement was:
    As at 31 March 2019, Pacific Edge has completed and invoiced a total of 17,015 tests for CMS patients in the USA, for which we are yet to be reimbursed.



    The other from your consolidated financial statements was:
    US customers – patients covered by CMS The Group has judged it is not probable that any consideration will be received from CMS as inclusion in the Local Coverage Determination (LCD) with the CMS has not yet been obtained. Therefore, no revenue is recognised for any patients covered by CMS"



    So, when you state ".. it is not probably that any consideration will be received from CMS", do you mean any consideration received won't be recognised in the period to 31 March, 2019?
    Or, do you mean that you don't expect to receive any consideration at all for the tests undertaken in that period on CMS patients?

    -----------------------------------------------------------------------------------------------------------------------------------------------

    Thanks for your email and questions on how the revenue from Cxbladder tests for CMS patients is recognised. There are two parts to this, as you have identified:


    1. Cumulatively to 31 March 2019, 17,015 tests have been performed for CMS patients for which Pacific Edge has not been paid. Until Cxbladder is included in the LCD, it is unknown what level of revenue will be received for these tests and because of this uncertainty, no revenue can be recognised. The accounting policy that you have picked up from the consolidated financial statements refers to the treatment of revenue in the 2018 and 2019 financial years.



    1. Once Cxbladder has been included in the LCD, Pacific Edge will discuss the reimbursement of all tests performed for CMS patients with the CMS. All 17,015 tests have been invoiced to the CMS but the discussion on payment for these tests can only be done once the LCD inclusion is obtained.


    Kind regards

    Pacific Edge Limited
    ----------------------------------------------------------------
    This raises 3 questions for me?

    (1) 17K tests is well beyond a trial- so why would PEB do so many unless they believed they would eventually get paid for them?

    (2) Would the US Government as the operator of CMS, not pay their bills to an important supplier, just because the required approval was received retrospectively?

    (3) If PEB can undertake 17K tests to date and there is an ongoing need for them and no indication that CMS are no longer wanting PEB to do them, won't this read to a big jump in eventual revenue?

    DYOR



  14. #16979
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    9,994

    Default

    Quote Originally Posted by Nigelk View Post
    This raises 3 questions for me?

    (1) 17K tests is well beyond a trial- so why would PEB do so many unless they believed they would eventually get paid for them?

    (2) Would the US Government as the operator of CMS, not pay their bills to an important supplier, just because the required approval was received retrospectively?

    (3) If PEB can undertake 17K tests to date and there is an ongoing need for them and no indication that CMS are no longer wanting PEB to do them, won't this read to a big jump in eventual revenue?

    DYOR


    [/FONT]
    Good they replied.

    I have some feedback from Florida where my biomed contact works and he tends to agree with you re payment from CMS once LCD inclusion is obtained.

  15. #16980
    Legend minimoke's Avatar
    Join Date
    Mar 2005
    Location
    Christchurch, New Zealand.
    Posts
    6,375

    Default

    ..........
    Last edited by minimoke; 20-06-2019 at 09:13 AM. Reason: Deleted by Minimoke in response to STMOD censorship of posts

Tags for this Thread

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •